Nephrology

Implementation Program to Improve Screening and management for CKD in Diabetes (IRIS-CKD)

Posted on by Jodi Snare

Page last updated December 8, 2025

ClinicalTrials.gov#: NCT06906627 - Program 1
ClinicalTrials.gov#: NCT06906640 - Program 2
Study Design: Prospective Observational Study
PCORnet Infrastructure: Patient partners or engagement
Principal Investigator: Neha Pagidipati
Institution: Duke Clinical Research Institute
PCORnet® Network Partner: The Coordinating Center for PCORnet®
Funder: Bayer, Boehringer Ingelheim, Lilly
Funding Date: 2024
Study Duration: 2024 – 2026
Participating PCORnet® Clinical Research Networks: INSIGHT, OneFlorida+, PaTH, REACHnet, STAR 
Therapeutic Area: Nephrology
Condition: CKD in Diabetes
Status: Recruiting

Research Question(s):
IRIS-CKD is a project focused on improving how doctors check for and treat chronic kidney disease (CKD) in people with type 2 diabetes (T2D). The main goals of the project are to:

  • Increase the number of people with type 2 diabetes who get screened for chronic kidney disease.
  • Ensure that more patients with both chronic kidney disease and type 2 diabetes receive the treatments recommended by medical guidelines.

USDHub: Community Resource for Urinary Stone Disease Research

Posted on by Jodi Snare

Page last updated August 22, 2025

Study Design: Other, Real World Evidence
PCORnet Infrastructure: Common Data Model (CDM), Single IRB, Patient partners or engagement
Principal Investigator: Ryan Hsi
Institution: Vanderbilt University Medical Center
PCORnet® Network Partner: STAR
Funder: NIH
Funding Date: 2024
Study Duration: 2024 – 2029
Participating PCORnet® Clinical Research Networks: PEDSnet, STAR
Therapeutic Area: Nephrology
Status: Active, not recruiting

Research Question(s): Can a data resource be created to strengthen urinary stone disease research that will generate new knowledge that improves the health of all individuals with urinary stone disease?

Choosing Immune Suppression in Renal Transplantation by Efficacy and Morbidity (CISTEM2)

Posted on by Jodi Snare

Page last updated February 20, 2026

Study Design: Retrospective Observational Study
PCORnet Infrastructure: Common Data Model (CDM), Patient partners or engagement
Principal Investigator: Vikas Dharnidharka and David Axelrod
Institution: University of Missouri
PCORnet® Network Partner: GPC
Funder: NIH
Funding Date: 2024
Study Duration: 2024 - 2029
Participating PCORnet® Clinical Research Networks: GPC
Therapeutic Area: Nephrology
Status: Active, not recruiting

Research Question(s): 

  1. Can we identify optimal immunosuppression management strategies for kidney transplant patients leveraging real world data?

Empagliflozin Diabetic Kidney Disease (Empa DKD)

Posted on by Jodi Snare

Page last updated February 5, 2026

ClinicalTrials.gov#: NCT05465317
Study Design: Retrospective Observational Study
PCORnet Infrastructure: Common Data Model (CDM), Patient partners or engagement
Principal Investigator: Neha Pagidipati
Institution: Duke Clinical Research Institute
PCORnet® Network Partner: The Coordinating Center for PCORnet®
Funder: Boehringer Ingelheim
Funding Date: 2021
Study Duration: 2021 – 2024
Participating PCORnet® Clinical Research Networks: OneFlorida+, PaTH, REACHnet, STAR
Therapeutic Area: Nephrology
Age Range: 18 Years and older (Adult, Older Adult)
Status: Completed

Research Question(s):

  1. Can we better understand why patients with type-2 diabetes may not receive guideline-recommended screening for diabetic kidney disease?
  2. Which medications may be most effective at improving kidney and heart outcomes in patients with and without type-2 diabetes?

Primary Publication(s):
Edmonston, D, Mulder, H, Lydon, E. et al. Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes. JACC. 2024 Aug, 84 (8) 696–708. doi.org/10.1016/j.jacc.2024.06.016

Edmonston D, Mulder H, Lydon E, et al. Kidney and Cardiovascular Effectiveness of Empagliflozin Compared With Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes. Am J Cardiol. 2024;221:52-63. doi:10.1016/j.amjcard.2024.04.011

Pediatric KIDney Stone (PKIDS) Care Improvement Network

Posted on by Jodi Snare

Page last updated October 29, 2025

Study Website: Pediatric KIDney Stone (PKIDS) Care Improvement Network
ClinicalTrials.gov#: NCT04285658
Study Design: Prospective Observational Study
PCORnet Infrastructure: Common Data Model (CDM), Single IRB, Patient partners or engagement
Principal Investigator: Gregory Tasian
Institution: The Children's Hospital of Philadelphia
PCORnet® Network Partner: PEDSnet
Funder: Patient-Centered Outcomes Research Institute (PCORI); (Project webpage)
Funding Date: 2019
Study Duration: 2020 – 2024
Participating PCORnet® Clinical Research Networks: GPC, OneFlorida+, PaTH, PEDSnet, STAR
Therapeutic Area: Nephrology
Condition: Kidney Stone; Nephrolithiasis
Age Range: 8 Years to 21 Years (Child, Adult)
Status: Completed

Research Question(s):

  1. What are the differences in stone clearance and the lived experiences of youth, age 8-21 years, following ureteroscopy (URS), shock wave lithotripsy (SWL), and percutaneous nephrolithotomy (PCNL) for the removal of kidney and ureteral stones?

Primary Publication(s):

Ellison JS, Lorenzo M, Beck H on behalf of the Pediatric KIDney Stone Care Improvement Network, et al. Comparative effectiveness of paediatric kidney stone surgery (the PKIDS trial): study protocol for a patient-centred pragmatic clinical trial. BMJ Open 2022;12:e056789. doi:10.1136/bmjopen-2021-056789

Preserving Kidney Function in Children with Chronic Kidney Disease (PRESERVE)

Posted on by Jodi Snare

Page last updated April 2, 2026

ClinicalTrials.gov#: NCT05169411
Study Design: Retrospective Observational Study
PCORnet Infrastructure: Common Data Model (CDM), Single IRB, Patient partners or engagement
Principal Investigator: Christopher Forrest
Institution: The Children's Hospital of Philadelphia
PCORnet® Network Partner: PEDSnet
Funder: Patient-Centered Outcomes Research Institute (PCORI); (project webpage)
Funding Date: 2021
Study Duration: 2021 – 2024
Participating PCORnet® Clinical Research Networks: GPC, OneFlorida+, PaTH, PEDSnet, STAR
Therapeutic Area: Nephrology, Rare Diseases
Condition: Chronic Kidney Disease Stage 2; Chronic Kidney Disease Stage 3; Pediatric Kidney Disease
Age Range: 1 Year to 17 Years (Child)
Status: Completed

Research Question(s):

  1. Which blood pressure monitoring strategies, urine protein monitoring strategies, and blood pressure medication strategies are most effective in preserving kidney function in pediatric patients with Chronic Kidney Disease (CKD), and what is the lived experience of families and patients living with pediatric CKD?